Mundipharma picks up chemo prodrug in $250M deal

Known as CAP7.1, the drug is a reformulated version of the generic agent etoposide and is designed to treat biliary tract cancer.

By Ned Pagliarulo • Aug. 15, 2017

Canadian drugmaker Prometic closes China JV deal

The Chinese pharmaceutical market is expected to grow dramatically, leading Western biopharmas to explore new partnerships and investments. 

By Suzanne Elvidge • Aug. 15, 2017

Fortress adds 10th subsidiary to biotech network

The hyrbid biopharma/venture firm launched Aevitas Therapeutics Monday to develop gene therapies for two rare diseases.

By Suzanne Elvidge • Aug. 15, 2017

Prescribed Reading: Merger as a band-aid for biotech troubles

Multiple biotechs with ongoing problems discovered solutions this week by merging with privately held companies, which could offer a needed boost. 

By Lisa LaMotta • Aug. 11, 2017

GSK drops two Ionis drugs in pipeline revamp

The British pharma, fresh off a review of its rare disease business, decided not to exercise options on inotersen and IONIS-FB-LRx.

By Jacob Bell • Aug. 11, 2017

Melinta grows pipeline through reverse merger with Cempra

The new company will focus on commercializing the pneumonia drug Baxdela and further developing its antibiotic platform.

By Jacob Bell • Aug. 9, 2017

Troubled Galena swallowed by Sellas

Sellas will take over the assets of struggling Galena in a reverse merger that allows the closely held company to go public.

By Lisa LaMotta • Aug. 9, 2017

Roche sells off dermatitis drug to Dermira

Lebrikizumab has had disappointing clinical results to date, yet Dermira hopes the IL-13 inhibitor could prove itself in the emerging atopic dermatitis space. 

By Ned Pagliarulo • Aug. 8, 2017

Mallinckrodt snaps up pediatric jaundice drug

The specialty pharma goes shopping in the baby-care aisle to pick up InfaCare and its pipeline of newborn medications.

By Suzanne Elvidge • Aug. 7, 2017

BMS boosts I/O pipeline with IFM acquisition

Bristol-Myers Squibb is buying its way into another immuno-oncology approach as it tries to maintain a leadership position. 

By Suzanne Elvidge • Aug. 4, 2017

Prescribed Reading: More portfolios reshuffled

Restructuring continued throughout the industry, as more companies attempt to cut costs or excess programs. Meanwhile, the FDA kept up its rapid pace of drug approvals.

By Lisa LaMotta • Aug. 4, 2017

Closing Claris deal, Baxter set to invest in three new plants

Baxter expects the injectable drugmaker will bring it $55 million worth of incremental sales during 2017.

By Jacob Bell • Aug. 3, 2017

Allergan's Saunders 'cautiously optimistic' on healthcare reform

The outspoken CEO talked Washington and drug pricing, as well as dealmaking, during a second quarter earnings call with analysts.

By Lisa LaMotta • Aug. 3, 2017

23andMe, Lundbeck unveil mega investigation of genetics' role in depression

Enrollment has already begun for the 25,000-person investigation.

By Jacob Bell • Aug. 2, 2017

Chiesi hands back gene therapy to uniQure

On the heels of Glybera's commercial flop, uniQure loses its development partner for a gene therapy currently in mid-stage testing for hemophilia B.

By Lisa LaMotta • Aug. 1, 2017

Bristol-Myers, Clovis ink industry's latest PARP deal

The companies plan to investigate the combination of Opdivo and Rubraca as a treatment for various cancers.

By Jacob Bell • Aug. 1, 2017

Evotec snaps up Aptuit in further CRO consolidation

Contract research organizations are merging at a rapid pace, at a time when their services are highly sought after by pharma and biotech companies.

By Suzanne Elvidge • Aug. 1, 2017

$40M cancer deal gets Redx out of the red

Loxo Oncology will pick up a cancer drug from the beleaguered U.K. company, helping Redx stave off financial woes.

By Suzanne Elvidge • Aug. 1, 2017

LabCorp strengthens its CRO standing with $1.2B Chiltern acquisition

The deal should expand the buyer's CRO workforce to more than 11,000 employees.

By Jacob Bell • July 31, 2017

Alexion leaves Moderna, others behind in R&D shake-up

The rare disease drugmaker's strategic review has led it to discontinue collaborations with the high-flying mRNA biotech as well as Blueprint and Arbutus.

By Jacob Bell • July 28, 2017

Prescribed Reading: Pharma marked by restructuring and failures

A week of earnings announcements emphasized changes in portfolios against the backdrop of a major pipeline failure. 

By Lisa LaMotta • July 28, 2017

J&J inks $879M vaccine deal with Bavarian Nordic

In another multimillion deal with the big pharma, the new alliance will focus on HIV and hepatitis B.

By Suzanne Elvidge • July 28, 2017

Tesaro lands licensing, supply agreements for Zejula

Two separate deals have Takeda handing over $100 million upfront for rights to the cancer med and STA Pharmaceutical providing the materials to make it.

By Jacob Bell • July 27, 2017

After MYSTIC miss, AstraZeneca taps Merck in $8.5B cancer deal

On the heels of its MYSTIC failure, the British pharma has teamed up with Merck to jointly develop and commercialize two of its oncology drugs.

By Lisa LaMotta • July 27, 2017

Mitsubishi Tanabe to acquire NeuroDerm for $1.1B

The Japanese pharma agreed to pay $39 per share of NeuroDerm, a 17% premium from the target's stock price at close-of-market July 21.

By Jacob Bell • July 24, 2017